Skip to Content
Søk Menu

SABCS20: Trastuzumab deruxtecan is a promising new treatment for HER2 positive metastatic breast cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Related

Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
BrystkreftESMO24 Play the Video 4:51
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
BrystkreftESMO24 Play the Video 1:23

New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

/ Jan Andreasen
BrystkreftESMO24

ESMO24: Breastfeeding After Breast Cancer Treatment Is Safe

/ Sofie Pohl
BrystkreftESMO24

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Brystkreft

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Brystkreft
László Tabár

Mammography Screening Is the Best Way to Reduce the Risk of a Premature Death from Breast Cancer

/ László Tabár
Brystkreft Play the Video 7:11

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24BrystkreftGastrointestinal kreft
Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
BrystkreftSABCS23 Play the Video 10:10
Back to top